

Media Contact: Kelli Wilder (650) 467-2086
Investor Contact: Kathee Littrell (650) 225-1034

<http://www.gene.com>

VACAVILLE PRODUCT OPERATIONS

1994

- Genentech announces it will locate its new \$250 million manufacturing facility in Vacaville, California, on October 31, 1994.
- As a "good neighbor" gesture and consistent with the company's commitment to science education, Genentech donates \$50,000 to the Vacaville Unified School District to install computer equipment for use by teachers and students.

1995

- In September, Genentech announces completion of final negotiations surrounding the purchase of its 100-acre site in the Vaca Valley Business Park from Chevron Land and Development Company.
- Also in September, construction begins on Vacaville Product Operations, providing the regional and Vacaville economies with several hundred construction jobs until the completion of the facility in 1998.

1996

- In May 1996, Genentech donates \$25,000 to Solano Community College in support of the college's planned biotechnology education program.

1998

- Genentech dedicates its new \$250 million manufacturing facility in Vacaville on October 23, 1998. The 310,000-square-foot operation includes five buildings and is the world's largest biotech manufacturing facility for the large-scale production of pharmaceutical proteins. The facility covers approximately 33 acres of the site.
- When the facility opens in 1998, approximately 160 individuals are employed in Vacaville.

2000

- Genentech's new state-of-the-art manufacturing facility in Vacaville receives U.S. Food and Drug Administration (FDA) licensure as a multi-product facility on April 25, 2000, allowing it to manufacture and distribute Herceptin® (Trastuzumab).
- The "Genentech Goes To Town" community relations program is launched in Vacaville, encouraging Genentech employees to spend GenenMoney within the local community during a special two-week period.

2001

- Genentech donates \$25,000 to support the expansion of the emergency room at NorthBay Medical Center in Fairfield, California.
- Vacaville Product Operations expands by adding a new 42,000 square foot warehouse and a 50,000 square foot administrative building, bringing the total area of the facility to 420,000 square feet.

2002

- The Genentech Foundation for Biomedical Sciences awards \$50,000 to Vacaville Unified School District in support of a Life Sciences High School in an effort to bring high quality science education programs to local schools.
- Vacaville Product Operations adds a 7,000 square foot product freezer, the largest of its kind in California. This addition brings the total square footage of the Vacaville facility to 427,000 square feet. The freezer can hold 360 pallets of product, is 28 feet high and has redundant systems to ensure consistent operations.
- In October, Vacaville Product Operations receives FDA licensure for the production and distribution of Rituxan® (Rituximab).

2003

- In June, Vacaville Product Operations receives FDA licensure for the production and distribution of Xolair® (Omalizumab).
- Genentech celebrates the fourth year of “Genentech Goes to Town” during September 2003 and sponsors the city’s Jazz Festival.

2004

- In August, the FDA approves the supplemental Biologics License Application (sBLA) for the manufacturing of Avastin® (bevacizumab) bulk drug substance at Vacaville Product Operations.

2005

- In March, Genentech donates \$500,000 to support construction of a new emergency room at VacaValley Hospital.

2007

- Frank Jackson, general manager of the Vacaville facility, announces his retirement. Effective July 9, Charles Calderaro III assumes the role of Genentech’s vice president and general manager, Vacaville Operations, succeeding Jackson.

###

(Last updated 11/9/09)